Because it lacks the immune-triggering Fc region of the full antibody, scFV minimises potential side effects. "Despite its small size, the fragment remained effective, reducing potential side ...

Maerivoet, A., et al. (2024) Enhanced stabilisation and reduced fibril forming potential of an amyloidogenic light chain using a variable heavy domain to mimic the homodimer complex. The FEBS ...

The ‘master key’ identified in this new paper is the antibody fragment V H Ab6, which was shown to be effective against the Alpha, Beta, Gamma, Delta, Kappa, Epsilon and Omicron variants.

KaloBios Pharmaceuticals is to receive $35 million up front from Sanofi Pasteur as part of the companies’ collaboration to develop KaloBios’ Phase II-stage antibody fragment KB001 for treating ...

A new study from Karolinska Institutet shows how a small antibody fragment can block fertilization by targeting a key protein on the surface of the egg. This discovery brings a non-hormonal ...